ArticleRespiratory medicine case reports2025
A case of EGFR-positive lung adenocarcinoma that once transformed into small cell carcinoma but worsened into adenocarcinoma again.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have a crucial role in the treatment of advanced EGFR mutated non-small lung cancer (NSCLC); however, most patients with EGFR-mutated NSCLC eventually develop acquired resistance to EGFR-TKIs. Small cell lung carcinoma (SCLC) transformation accounts for about 10 % of the mechanisms of acquired resistance of EGFR-TKIs, and the type of anticancer drugs used for treatment must change drastically when transformation occurs. We herein report a case of a patient with EGFR-positive lung adenocarcinoma that transformed into small cell carcinoma but worsened into adenocarcinoma again, by accurately identifying the lung cancer stage and selecting appropriate treatment thorough repeated re-biopsy. In this report, the accurate diagnosis through repetitive re-biopsy and tumor marker measurements in different histologic types was critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.